Providers

Provider Resource Center

Research

Ketamine in Major Depressive and Bipolar Disorder: A Meta-Analysis Review

This systematic review and quantitative meta-analysis, published in General Hospital Psychiatry, evaluates ketamine's efficacy as a novel treatment for major depressive disorder and bipolar depression. Analyzing randomized placebo-controlled trials, the study reveals that ketamine significantly reduces depressive symptoms, with substantial effects evident from day 1 and sustained at least a week post-infusion. The findings demonstrate ketamine's rapid onset, high efficacy, and good tolerability, offering new hope in the pharmacotherapy of depression and bipolar disorders. This comprehensive analysis underscores ketamine's potential as a groundbreaking intervention in mental health treatment.

Financial Services

Manage your account or make a payment.

Disclaimers

Financing Disclaimer: $325/month for Uplift Momentum Protocol™ (medical procedure), financed over 12 months with a total cost of $3,900, 0% interest. Approval based on internal criteria, including bank account history and a soft credit pull. Payments are auto-withdrawn monthly . Subject to $25 late fee for missed payments and other terms. Cancellation within 3 days of agreement allowed. Governed by California law and AAA arbitration rules. View Terms & Conditions

Important Medical Disclaimers

Individuals showcased on KetamineUplift.com are actors, the content is not reflective of their thoughts, views, or perspectives.

Patients

Home
Science
Experience
Program
About
FAQ's
Financial Services
Contact

Providers

Provider Home
Practice Info
Resources
Research
Patient Referrals
Schedule Tour

Get in touch

(310) 280-4440
care@ketamineuplift.com

4640 Admiralty Way
Suite 718A
Marina del Rey, CA 90292

Directions

© 2024 Ketamine Uplift | Terms of Service | Privacy Policy